A Scribe spokesperson said, "The company's gene-editing therapy aims to permanently modify a gene that regulates cholesterol production, potentially offering a single-dose solution." Scribe employs the CRISPR system to achieve exact modifications within the human genome.
For the quarter ending March 31, Scribe reported a net loss of $17.4 million and collaboration revenue of $2.2 million. In the same period a year earlier, Scribe recorded a net loss of $3.5 million and collaboration revenue of $17.1 million, per its filings.
Globally, heart disease is the leading cause of mortality, and conventional treatments like statins need continuous use. Scribe's approach aims for a permanent genetic modification that could fundamentally alter disease management, moving from daily pills or regular injections to a one-time intervention. This strategy mirrors advances in gene editing for other conditions, such as sickle cell disease, and could dramatically reduce the burden on patients and healthcare systems if proven safe and effective. The PCSK9 target is already validated by approved injectable drugs, but those require repeated doses; a single-dose gene edit would remove that compliance hurdle entirely.
Get the market news that matters in a five-minute read with Market Briefs, our free daily newsletter
The potential market for a one-time gene-editing therapy for cardiovascular disease is vast. Millions of patients worldwide currently rely on daily statins or periodic injections, and even modest adoption could yield substantial revenue. Yet significant challenges remain, such as ensuring long-term safety and scaling up manufacturing.
Gene editing for cardiovascular disease represents a frontier in biotechnology, with several companies exploring approaches to lower LDL cholesterol permanently. Scribe's candidate targets the PCSK9 gene, which plays a key role in cholesterol metabolism. If successful, the therapy could compete with existing PCSK9 inhibitors like Repatha and Praluent, which require regular injections.
Scribe's backers also include investors tied to Avoro Life Sciences Fund and Andreessen Horowitz, alongside Eli Lilly. Given the high prevalence of cardiovascular disease and the limitations of current therapies that require continuous use, a successful gene-editing treatment could represent a paradigm shift. The company's cash runway from the IPO will support its lead program through early clinical milestones.
The IPO is being underwritten by Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo & Co. Scribe anticipates its shares will be listed on the Nasdaq Global Market under ticker SCTX. The offering is expected to price in the coming days, and its outcome will serve as a gauge for investor appetite toward early-stage gene-editing companies in the current market environment.
If successful, Scribe's candidate would offer a one-time alternative to daily statins or repeated injections of PCSK9 inhibitors. The Australian trial will provide an early read on safety and efficacy in humans.
Proceeds from the IPO are intended to fund clinical development through key data readouts, including the upcoming Australian trial results.
Join Market Briefs, our free daily newsletter, for a quick daily rundown of the markets
